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Summary
The acute myeloid leukemia (AML)-associated CBFb-SMMHC fusion protein impairs hematopoietic differentiation and pre-
disposes to leukemic transformation. Themechanism of leukemia progression, however, is poorly understood. In this study,
we report a conditional Cbfb-MYH11 knockin mouse model that develops AML with a median latency of 5 months. Cbfb-
SMMHC expression reduced the multilineage repopulation capacity of hematopoietic stem cells (HSCs) while maintaining
their numbers under competitive conditions. The fusion protein induced abnormal myeloid progenitors (AMPs) with limited
proliferative potential but leukemic predisposition similar to that of HSCs in transplanted mice. In addition, Cbfb-SMMHC
blocked megakaryocytic maturation at the CFU-Meg to megakaryocyte transition. These data show that a leukemia onco-
protein can inhibit differentiation and proliferation while not affecting the maintenance of long-term HSCs.Introduction
Acute myeloid leukemia (AML) arises from clonal expansion
of hematopoietic progenitors that have acquired genetic alter-
ations. Recurrent chromosomal rearrangements frequently
found in AML create fusion proteins that alter differentiation,
proliferation, and survival programs as part of the multistep pro-
cess of leukemogenesis (Look, 1997). For example, the inver-
sion of chromosome 16 inv(16)(p13.1q22) [henceforth inv(16)]
breaks and joins the CBFB gene with the myosin gene
MYH11, creating the CBFB-MYH11 fusion that encodes
CBFb-SMMHC (Liu et al., 1993, 1996).
The transcription factor core binding factor (CBF) regulates
a variety of hematopoietic genes associated with lymphoid
and myeloid differentiation (Otto et al., 2003). CBF is a hetero-
dimeric complex that includes the CBFb subunit, encoded by
CBFB, and a DNA binding a subunit, encoded by one of three
RUNX family members (RUNX1, RUNX2, or RUNX3). CBFb is
critical for CBF function, as it increases the affinity of RUNX pro-
teins for DNA (Ogawa et al., 1993; Wang et al., 1993) and seems
to protect these a subunits from proteolytic degradation (Huang
et al., 2001). CBF is the most common target of alterations inCANCER CELL 9, 57–68, JANUARY 2006 ª2006 ELSEVIER INC. DOI 10.1human AML. In addition to inv(16) that affects CBFB, AML
samples often harbor RUNX1 alterations, including t(8;21) and
loss-of-function mutations (Speck and Gilliland, 2002).
Studies using Runx1 and Cbfb knockout mice have deter-
mined that the lack of either subunit abrogates the development
of embryonic definitive hematopoiesis, and embryos die
at midgestation (Niki et al., 1997; Okuda et al., 1996; Sasaki
et al., 1996; Wang et al., 1996a, 1996b). Furthermore, Runx1
was shown to be critical in the emergence of hematopoietic
stem cells (HSCs) from the hemogenic endothelium (Speck
and Gilliland, 2002). Consistent with these studies, definitive he-
matopoiesis was absent in heterozygous Cbfb-MYH11 knockin
embryos, underscoring the dominant-negative effect of the
fusion protein on CBF function (Castilla et al., 1996; Yergeau
et al., 1997). Using the Cbfb-MYH11 knockin chimeras, we
have shown that Cbfb-SMMHC expression alters adult multilin-
eage hematopoietic differentiation (Castilla et al., 1999). The
multistep nature of leukemia progression in inv(16) AML was
also demonstrated in these mice where gain of additional muta-
tions, induced by chemical or retroviral mutagens, was neces-
sary for the development of AML (Castilla et al., 1999, 2004).
However, the embryonic lethality observed in the heterozygousS I G N I F I C A N C E
CBFb-SMMHC is a fusion oncoprotein that is present in approximately 12% of human AML and interferes with the core binding factor
transcription factor regulation of hematopoietic differentiation. Studies in the mouse have been limited due to the embryonic lethality
caused by its expression. Here, we use a conditional mouse model for CBFb-SMMHC to demonstrate that leukemia-associated fusion
proteins can impair multilineage differentiation while not expanding long-term HSCs. Furthermore, the identification of CBFb-SMMHC-
induced AMPs suggests that these leukemia-prone populations may be a common theme among leukemia fusion oncogenes. More-
over, we have developed a conditional mouse model where the efficacy of novel therapeutics designed to induce differentiation of
the leukemic cells can be evaluated.016/j.ccr.2005.12.014 57
A R T I C L EFigure 1. Generation of a conditional Cbfb-MYH11 knockin mouse model
A: Schematic representation of targeting strategy. The CbfbMYH11 allele (exons in black boxes; neomycin gene ‘‘N’’) was targeted by homologous recombi-
nation. Between loxP1 sites (triangles), the targeting construct included the 30 end of intron 4 with the splice donor signal (#) and the beginning part of exon 5,
an in-frame cDNA sequence for the second part of human exon 5 and exon 6 (open boxes), the bovine growth hormone polyadenylation signal (A), and
PGK-hygromycin gene (H). This sequence was inserted in an MscI site (M) of intron 4. TheCbfbMYH11 allele is restored upon Cre-mediated deletion of the floxed
sequence.58 CANCER CELL JANUARY 2006
A R T I C L Eknockin mice and the lack of an inv(16) conditional knockin
mouse model have limited detailed in vivo studies of Cbfb-
SMMHC effects in hematopoietic differentiation, proliferation,
and survival during leukemia progression.
In this study, we created a conditional Cbfb-MYH11 knockin
mouse model to analyze the preleukemic effects of Cbfb-
SMMHC in hematopoiesis and the development of AML. Upon
Cre-mediated induction of Cbfb-SMMHC in adult mice, the
numbers of B cells and platelets were markedly reduced in the
peripheral blood, and an abnormal myeloid progenitor (AMP)
population was detected in the bonemarrow (BM). In vitro differ-
entiation and serial replating assays demonstrated that the my-
eloid progenitors had a deficient proliferation capacity. These
findings were replicated in vivo using BM transplantation as-
says, underscoring the cell-autonomous nature of the pheno-
type. Furthermore, competitive repopulation assays (CRA) re-
vealed that HSCs expressing Cbfb-SMMHC were maintained
at normal levels for long periods, but interestingly, their long-
term multilineage repopulation capacity was severely compro-
mised. In addition, knockin mice expressing Cbfb-SMMHC
developed AMLwith a median latency of 5months, in which dis-
ease onset varied with the number of leukemia precursors in the
BM. Finally, limiting dilution transplantation assays revealed that
AMPs have similar leukemic transforming capacity as HSCs.
The results of this study provide in vivo evidence that leukemia
fusion proteins that affect hematopoietic differentiation may
maintain normal number of HSCs with deficient repopulation
function, while creating preleukemic myeloid progenitors that
can be targets for AML transformation.
Results
Creation of a conditional Cbfb-MYH11 knockin allele
The study of Cbfb-SMMHC function in adult hematopoiesis and
leukemia in the mouse has been limited due to the embryonic
lethality of the heterozygous Cbfb+/MYH11 knockin (Castilla
et al., 1996). We generated a conditional Cbfb-MYH11 knockin
mouse model, called Cbfb+/56M, in which Cbfb exons 5 and 6
flanked by loxP1 sites were inserted at an Msc1 site in intron 4
(Figure 1A). Under this design, the wild-type Cbfb transcript is
expressed from the ‘‘floxed’’ Cbfb56M allele. Upon Cre expres-
sion, the knockin allele is restored and Cbfb-SMMHC activated.
For clarity, mice and cells containing this allele will be called ‘‘re-
stored.’’ HeterozygousCbfb+/56M and homozygousCbfb56M/56M
mice were born in Mendelian ratios and remained healthy over
1 year of age, indicating the expression of a functional Cbfb
from the floxed allele. Cbfb-MYH11 function was confirmed in
vivo using the EII-Cre transgene, in which Cre is under the con-
trol of the adenovirus EIIa promoter and is expressed in early
embryogenesis at 2–8 cell stage (Lakso et al., 1996). Cbfb+/56M/
EII-Cre embryos recreated the definitive hematopoiesisCANCER CELL JANUARY 2006deficiency and midgestation lethality phenotypes previously re-
ported (Castilla et al., 1996; data not shown). In addition, traces
of Cbfb-SMMHC protein were detected in BM from controls
(Figure 1B, lanes 2 to 5), probably due to alternative splicing
that bypassed the floxed sequences. Fusion protein levels
were effectively induced 12- to 15-fold in the BM fromCbfb+/56M
mice using the Mx1Cre system (Kuhn et al., 1995) (Figure 1B).
The efficiency of Cre-mediated deletion at the Cbfb56M allele
in hematopoietic progenitors was assessed in hematopoietic
tissues by Southern blot analysis as a function of time following
polyinosinic-polycytidylic acid (pIpC) injection. After 1 week,
over 80% of 5FU-treated restored BM progenitors and 50% of
spleen cells had undergone Cre-mediated deletion, while no de-
tectable deletion was observed in liver and thymus (Figure 1C,
top panel). Similar analysis of untreated restored BM showed
a 30% to 50%deletion (data not shown). The percentage of cells
in the thymus with the deletion increased significantly after the
third week, suggesting that T cell precursors expressing Cbfb-
SMMHCmay have migrated into the thymus (Figure 1C, bottom
panel). In addition, time course analysis of peripheral blood from
restored Cbfb+/56M/Mx1Cre and control Cbfb+/56Mmice by fluo-
rescence-activated cell sorter (FACS) analysis revealed that
B cells (B220+) were significantly reduced at 4 weeks and re-
mained low throughout the experiment, while myeloid cells
(Mac-1+ andGr-1+) and T cells (CD3+) appeared unaffected (Fig-
ure 1D). Moreover, platelet counts were reduced 50%, while he-
matocrits remained unaltered, suggesting that the fusion protein
may interfere with megakaryocytic maturation. To examine
whether expression of Cbfb-SMMHC stimulated apoptosis of
hematopoietic cells, we also performed FACS analysis of BM
and peripheral blood with annexin V and lineage makers
(Mac1, Gr1, CD3, and B220) from primary restored and control
mice. No detectable differences between these groupswere ob-
served, suggesting that Cbfb-SMMHC does not induce apopto-
sis (data not shown).
Cbfb-SMMHC impairs competitive repopulation while
not affecting maintenance of the phenotypic HSCs
Cbfb-SMMHC impairs hematopoietic differentiation in knockin
chimeric mice (Castilla et al., 1999). To our surprise, myeloid
and T cell differentiation from primary restored mice (treated
Cbfb+/56M/Mx1Cre; Figure 2A) remained unaltered for 12 weeks
after treatment (Figure 1D). To test the effects of Cbfb-SMMHC
expression in HSCs, we analyzed the phenotypic HSC compart-
ment (Lin2/c-Kit+/Sca1+; LKS+) by FACS. The HSCs from pri-
mary restored mice increased 2- to 3-fold compared to similarly
treated littermate controls (Figure 2B, dashed box).
To assess whether this increase was cell autonomous, we an-
alyzed the effect of Cbfb-SMMHC using noncompetitive re-
population assays (NCRA; Figure 2A). Lethally irradiated mice
were transplanted with 1 3 106 floxed or control BM cells.B: Western blot analysis of Cbfb-SMMHC induction. BM protein extracts included wild-type (lane 1),Cbfb+/56M (lanes 2 and 3),Cbfb56M/56M (lane 4),Cbfb+/56M/
Mx1Cre (lane 5), and pIpC-treated Cbfb+/56M/Mx1Cre (lanes 6–8). Bands corresponding to Cbfb, Cbfb-SMMHC, and a-tubulin are depicted on the right. An
unspecific band corresponding to mouse IgG light chain reactive to secondary antibodies is also shown (asterisk).
C: Southern blot analysis of Cre-mediated restoration of theCbfbMYH11 allele in 5FU-enriched bone marrow (BM), spleen (SP), liver (LV), and thymus (TH) 1 week
after pIpC treatment (top panel). Time course analysis in spleen and thymus at 1 week (1w), 2 weeks (2w), 3 weeks (3w), and 4 weeks (4w) after pIpC treatment
is depicted (bottom panel).
D: Time course (2–12 weeks) FACS analysis of peripheral blood cells from pIpC-treated Cbfb+/56M/Mx1Cre (squares) and littermate control (diamonds) mice.
Lineage-specific (Gr-1+, Mac-1+, CD3+, and B220+) peripheral blood cells, hematocrit (HCT), and platelet counts are shown as mean + standard deviation
(*p < 0.01; two-tailed Student’s t test; n = 6).59
A R T I C L EFigure 2. Cbfb-SMMHC impairs competitive repopulation while not affecting the number of phenotypic HSCs
A: Flow chart depicting the experimental approaches used in this study. PrimaryCbfb+/56M/Mx1Cre floxed or control mice were analyzed 3–6 weeks after pIpC
treatment. In noncompetitive repopulation assays (NCRA), test (floxed or control) BM cells were transplanted into lethally irradiated recipients and pIpC
treated 2 weeks later. Contribution to peripheral blood was analyzed biweekly for 12 weeks. BM was analyzed at 18 weeks followed by secondary transplan-
tation. In competitive repopulation assays (CRA), 53 105 BM test (floxed or control) and competitor cells were mixed and transplanted into lethally irradiated
recipients. See Experimental Procedures for details.
B: FACS analysis of primary (restored and control) HSCs (dashed box; n = 6; *p = 0.042) and myeloid progenitors (solid box; n = 6; **p = 0.0007).
C and D: Histogram representations of donor-derived BM contribution in NCRA (C) and test/competitor ratio in CRA (D), including control (gray) and restored
(black) cells. Left: contribution to whole BM, lineage-positive (Lin+), and lineage-negative (Lin2) progenitors. Right: contribution to HSCs (LKS+) and progenitors
(LKS2). NCRA (mean + SD; n = 4); CRA (mean ratio of test to competitor + SD; n = 3; *p = 0.05).
E: Time-lapse contribution of restored (squares) or control (diamonds) cells to peripheral blood in CRA (n = 8–-10; *p < 0.05; **p < 0.01; ***p < 0.001).Similar engraftment of floxed and control BM was confirmed
prior to induction of Cbfb-SMMHC. Transplanted recipients
(floxed and control) were then treated with seven doses of
pIpC to ensuremaximum induction of fusion protein expression.
FACS analysis of peripheral blood 2–12 weeks after pIpC treat-
ment showed similar lineage contribution as in primary restored
mice (data not shown). Analysis of BM 18 weeks posttreatment
indicated similar contribution between restored and control do-
nor cells in whole BM, and lineage-restricted (Lin+) and myeloid
progenitor (LKS2) compartments (Figure 2C, left panel). How-
ever, restored donor-derived long-term phenotypic HSCs (LKS+)
were increased 2- to 8-fold (Figure 2C right panel), confirming
that Cbfb-SMMHC-induced HSC expansion is cell autonomous.
To test the proliferative capacity of BM progenitors express-
ing Cbfb-SMMHC, we analyzed their expansion in CRA (Fig-
ure 2A). Equal numbers of test (control or floxed; 129 SvEv60strain; Ly9.1+) and competitor (wild-type C57BL/6-SJL strain;
Ly5.1+) cells were mixed and transplanted into lethally irradiated
recipients (C57BL/6-SJL strain; Ly5.2+). Similar engraftment be-
tween restored and control donors was confirmed before pIpC
treatment (see Figure 2E, 0 time point). The contribution of re-
stored donors to whole BM, lineage-restricted (Lin+), and mye-
loid progenitors (Lin2/c-Kit+/Sca12; LKS2) was significantly re-
duced under competitive conditions (Figure 2D, left panel). In
contrast, restored and control donors weremaintained at similar
numbers in the long-term HSC (LKS+) compartment (Figure 2D,
right panel). Biweekly FACS analysis of peripheral blood re-
vealed a significant reduction of restored donors in all lineages
analyzed (Figure 2E). Furthermore, restored BM cells engrafted
into secondary transplants and showed a deficient multilineage
repopulation at 8 weeks, similar to that found in primary trans-
plants. Secondary transplants developed AML between weeksCANCER CELL JANUARY 2006
A R T I C L EFigure 3. Cbfb-SMMHC induces an AMP compartment
A: FACS analysis of the myeloid compartment (LKS2; solid box in Figure 2B) in primary mice. Distinct CMP (CD34+/FcgRII/IIIlow), MEP (CD342/FcgRII/III2), and
GMP (CD34+/FcgRII/IIIhi) subpopulations are shown in control mice (left panel).
B and C: In vitro erythroid and myeloid differentiation assays of primary restored and control cells in methylcellulose. B: White bars represent CFU-E, black bars
represent BFU-E, and gray bars represent CFU-myeloid (mean + SD; n = 4 in duplicates).C: Percentage of each type of colony determined based on morphol-
ogy of cytospin preparations scored from 60 colonies from each of four independent assays (striped bar, CFU-blast; gray bar, CFU-GEMM; black bar, CFU-GM;
white bar, CFU-G; diagonally striped bar, CFU-M; mean + SD; n = 4 in duplicates).
D: Representative images of myeloid colonies at day 7 depicting an increased number of smaller colonies in restored cultures.
E: Serial replating assays of 1 3 104 pooled restored or control cells at day 7 (mean + SD; n = 3 in duplicates).12 to 16, probably due to acquisition of transforming mutations
(data not shown). Together, these results show that HSCs ex-
pressing Cbfb-SMMHC can be maintained for long periods in
transplanted mice, although their multilineage repopulation ca-
pacity is markedly compromised.
Expression of CBFb-SMMHC generates
an AMP compartment
To assess the role of Cbfb-SMMHC in the myeloid progenitor
compartment, we analyzed the LKS2 fraction from primary
BM by FACS (Akashi et al., 2000). Restored myeloid progenitors
increased 3- to 9-fold when compared to littermate controls
(Figure 2B, solid box). Notably, the myeloid progenitor compart-
ment included a predominant AMP population that could not be
further separated into distinct common myeloid progenitor
(CMP; CD34+/FcgRII/IIIlow), myeloid-erythroid progenitor (MEP;
CD342/FcgRII/III2) and granulocyte-macrophage progenitor
(GMP; CD34+/FcgRII/IIIhi) subpopulations (Figure 3A). Due to
their apparent MEP-like immunophenotype (LKS2/CD342/
FcgRII/III2), we tested whether AMPs could differentiate into
myeloid and erythroid lineages in vitro. Methyl-cellulose cultures
from restored BM consistently generated a 1.5- to 2.5-fold in-
crease in erythroid and myeloid colonies (Figure 3B). Analysis
of myeloid colonies revealed an increase in CFU-GEMM and re-
duction of CFU-GM, indicating that AMPs have a CMP-likeCANCER CELL JANUARY 2006differentiation capacity (Figure 3C). Furthermore, restored BM
cultures showed a significant increase of smaller colonies
when compared to controls (Figures 3D and 3E, plating 1). Ap-
proximately 90% of these colonies contained the Cre-mediated
deletion when tested by single-colony PCR (data not shown),
thus confirming Cbfb-SMMHC expression. Moreover, serial re-
plating assays of BM cells from primary restored mice showed
that the replating capacity of AMP-derived CFUs was markedly
lower than that of wild-type controls (Figure 3E). These results
show that the fusion protein induces the creation of AMPs
with an MEP-like immunophenotype, a CMP-like differentiation
potential, and reduced proliferation capacity.
Cbfb-SMMHC blocks megakaryocytic differentiation
Previous studies have implicated CBF as a key regulator of ter-
minal megakaryocytic maturation. Patients with familial platelet
disorder have been linked to heterozygous RUNX1 mutations
and are predisposed to AML (Song et al., 1999). Recent studies
using Runx1 conditional knockouts reported that Runx1 null or
haploinsufficient mice exhibited deficient terminal megakaryo-
cytic differentiation (Growney et al., 2005; Ichikawa et al.,
2004; Sun and Downing, 2004). Our findings that Cbfb-SMMHC
alters the myeloid progenitor compartment and reduces platelet
counts prompted us to assess its effect onmegakaryocyticmat-
uration. Analysis of primary restored BM sections 3–4 weeks61
A R T I C L EFigure 4. Cbfb-SMMHC impairs megakaryocytic maturation
A: H&E-stained BM histology sections of restored and control mice. Higher magnification of the boxed area in the top panels is shown in the bottom panels.
Mature megakaryocytes (arrow) and immature megakaryocytes (arrowhead) are shown. Scale bars, 50 mm.
B: Differentials of immature and mature megakaryocytes in BM (mean + SD; n = 4; *p < 0.02).
C: DNA ploidy of CD41+ BM cells (red solid lines) and CD412 factions (black dashed lines). Typical results are shown (n = 2–6).
D: Flow cytometric analysis of CFU-Meg (Lin2/c-Kithi/CD41hi) fraction (n = 6 ; **p < 0.013).after induction revealed a 14-fold reduction in mature megakar-
yocytes (abundant cytoplasm and lobulated nucleus; Figure 4A,
arrow; Figure 4B) and 2.3-fold reduction of immature megakar-
yocytes (large cytoplasmwith regular nucleus; Figure 4A, arrow-
head; Figure 4B). The deficiency in mature megakaryocytes was
also evident by flow cytometric measurement of DNA content,
as CD41+ restored BM presented a marked reduction in 16N
cells concomitant with an increase in 2N cells (Figure 4C). In ad-
dition, we observed a 2 fold increase of CFU-Meg progenitors
(Lin2/c-Kithi/CD41hi fraction), which give rise to immaturemega-
karyocytes (Figure 4D; Hodohara et al., 2000). These results
demonstrate that Cbfb-SMMHC impairs megakaryocyte matu-
ration at the CFU-Meg to immature megakaryocyte transition.
Cbfb-SMMHC induces spontaneous AML
We have previously shown that Cbfb-SMMHC is necessary but
not sufficient to cause leukemia (Castilla et al., 1999, 2004).62Surprisingly, 90% of primary restored mice developed AML be-
tween 11 and 24 weeks of age when treated with three doses of
pIpC (Figure 5A, solid line). We reasoned that the observed dif-
ference in AML development between the restoredmice and the
knockin chimeras may reside on the number of Cbfb-SMMHC-
expressing progenitors in the BM.We tested this hypothesis us-
ing two independent assays. First, whenmicewere inducedwith
only one dose of pIpC, AML latency was delayed to 21 weeks
with 15% efficiency by 24 weeks (Figure 5A, dashed line). The
proportion of restored cells between three (17% 6 4.8) and
one (6%6 2.9) pIpC doses was approximately 2:1, 1 week after
treatment when tested by qPCR (Figure S1A in the Supplemen-
tal Data available with this article online). Second, when titrating
numbers of restored BM cells (3 3 106, 1 3 106, or 0.5 3 106)
were transplanted into irradiated recipients, AML was observed
only in the first group (33 106), with 70% efficiency at 26 weeks,
while recipients harboring 13 106 or 0.53 106 restored BMcellsCANCER CELL JANUARY 2006
A R T I C L EFigure 5. Cbfb-SMMHC-associated AMPs prog-
ress to leukemia
A: Kaplan-Meier survival curve of Cbfb+/56M/
Mx1Cre mice induced at 3 weeks (arrow) with
one (dashed line, n = 16) or three (solid line, n =
28) doses of pIpC.
B: Wright-Giemsa staining of peripheral blood
from a leukemic mouse depicting immature cells
with predominant monocytic (arrow) and blast-
like (arrowheads) progenitors; scale bars, 5 mm.
C: FACS analysis of myeloid progenitor compart-
ment of spontaneous leukemia (left panel) and
PLAGL2-induced leukemia (right panel). Typical
results are shown (n = 4–7).
D: In vitro differentiation assay of leukemic cells
and untreated controls. Myeloid colonies (green
bar, CFU-blast; gray bar, CFU-GEMM; black bar,
CFU-GM; white bar, CFU-G; red bar, CFU-M)
were identified based on morphology of cyto-
spin preparations scored from 60 colonies from
each of four independent assays.
E: Quantitative RT-PCR of Plag1 and PlagL2 in
a panel of 20 spontaneous AML samples. The
threshold of Plag1 and PlagL2 leukemic function
was defined at relative expression levels (RELs) of
5, as indicated by the dashed line. RELs shown
represent the average values of two indepen-
dent experiments.aswell as wild-type controls remained disease free (Figure S1B).
In all cases tested, the leukemic nature of these cells was con-
firmed in secondary transplantations. Together, these results
support the hypothesis that the latency and penetrance of dis-
ease depend on the size of progenitor population at risk to de-
velop full-blown disease after acquiring cooperating mutations.
The pathology of the disease was consistent with AML devel-
oped in knockin chimeras, including splenomegaly, infiltration in
spleen and liver, leukocytosis, and anemia (see Figure S2; Cas-
tilla et al., 1999). Multiparameter analysis of these spontaneous
AMLs with myeloid progenitor compartment markers showed
that the predominant leukemic population presented an AMP-
like immunophenotype (LKS2/CD342/FcgRII/III2; Figure 5C,
left panel). Furthermore, immunophenotype analysis using 28
hematopoietic markers and cytology examination determined
that leukemic cells included two main subpopulations. A pre-
dominant blastlike population represented approximately 85%
of AML cells and was characterized as c-kit+, CD45lo, and
CD71mod (Figure 5B, arrowheads; and Table S1). A second
monocytic population represented approximately 15% of AML
and was Gr1+, Mac1+, Ly71(F4/80)+, CD45+, CD24+, CD16/32+,CANCER CELL JANUARY 2006CD31+, CD59+, CD71lo, and CD86+ (Figure 5B, arrows; and
Table S1). Spectral karyotyping analysis of leukemic samples
(n = 5) revealed no clonal chromosomal abnormalities (data
not shown), consistent with the hypothesis that Cbfb-SMMHC
does not induce genomic instability. Analysis of the in vitro dif-
ferentiation potential of spontaneous AMLs revealed a predom-
inance of immature colonies (CFU-blast and CFU-GEMM;
Figure 5D). In addition, the serial replating capacity of AML cells
was sustained up to plating 5 (data not shown). These data show
that the deficient proliferation potential observed in AMPs is
restored in leukemic cells. However, leukemic cells do not
show in vitro immortalization, probably due to their dependency
on cytokines and/or growth factors that are not present in these
cultures.
To test whether Cbfb-MYH11-mediated spontaneous AML
samples present deregulated expression of cooperating genes,
we analyzed the expression levels of Plag1 and Plagl2 by qPCR
in a panel of 20 spontaneous AML samples. First, we defined the
threshold of Plag1 and PlagL2 leukemic function based on their
transcript levels inMIG-Plag1- andMIG-PLAGL2-induced AML
samples (relative expression levels [RELs] R 4.5; unpublished63
A R T I C L ETable 1. Limiting dilution transplantation of sorted HSCs and myeloid progenitors
Starting
population
Gene
alteration
Transduction
efficiency (%)
Transplanted
cells
Estimated
transduced cells
Transplanted
animals
Incidence
of AML (%)
Latency
(weeks 6 SD)
HSC (LKS+) Cbfb-MYH11 + PLAGL2 30 10,000 3000 4 100 12.8 6 3.9
1000 300 4 75 15.7 6 3.8
100 30 5 20 11
HSC (LKS+) wild-type + PLAGL2 30 2000 600 5 0 na
AMPs (LKS2) Cbfb-MYH11 + PLAGL2 30 10,000 3000 4 100 12.8 6 3.9
1000 300 4 75 15.7 6 3.8
100 30 5 20 11
Myeloid progenitors (LKS2) wild-type + PLAGL2 30 200,000 60,000 5 0 na
20,000 6000 5 0 na
na, not applicable.data; and Landrette et al., 2005). Spontaneous AMLs showed
significant Plag1 overexpression in 20% (4/20) of the samples
and PlagL2 in 30% (6/20) of the samples (Figure 5E). These re-
sults highlight the deregulation of Cbfb-MYH11 cooperating
genes in spontaneous AMLs. Furthermore, considering that
PLAG1 and PLAGL2 were found overexpressed in 20% of hu-
man AML samples, these observations underscore the rele-
vance of this model to human disease.
It is thought that leukemia rises from the accumulation of mu-
tations in the HSCs (Reya et al., 2001). Our finding that Cbfb-
SMMHC creates a unique myeloid progenitor (AMPs) prompted
us to test whether this restricted progenitor behaves as a leuke-
mic precursor at similar frequency as HSCs upon the acquisition
of other mutations. We have previously reported that while
PLAGL2 andCbfb-SMMHCcooperate in AML development, ex-
pression of either transcription factor independently is insuffi-
cient to cause AML (Landrette et al., 2005). On this basis, we
compared the ability of HSCs (LKS+) and AMPs (LKS2) to induce
AML using limiting dilution BM transplantation assays. Sorted
LKS+ and LKS2 cells from primary restored BM were trans-
duced with MIG-PLAGL2 and transplanted into sublethally irra-
diated recipients at various diluted concentrations (13 104, 13
103, and 1 3 102 cells). Mice transplanted with either LKS+ or
LKS2 cells developed AML with similar latency (9–12 weeks),
and the disease penetrance correlated with the number of pro-
genitors transplanted (Table 1). Control groups confirmed that
PLAGL2 is not sufficient to induce AML when transduced into
wild-type HSCs or myeloid progenitors. The disease was readily
transplantable to secondary recipients with short latency. In ad-
dition, the leukemic cells were GFP+, indicating the expression
of MIG-PLAGL2 (data not shown). The pathology of disease
was similar in both groups, and resembled that of spontaneous
AML. Likewise, multiparameter flow cytometry analysis of these
AML cells showed an AMP-like immunophenotype irrespective
of the initial transduced population (Figure 5C, right panel). To-
gether with the marked expansion observed in the primary re-
stored mice, these results show that AMPs represent a unique
Cbfb-SMMHC-expressing progenitor at risk for leukemia devel-
opment.
Discussion
In this study, we used a Cbfb-MYH11 conditional knockin
mouse model to analyze the effect of Cbfb-SMMHC in leukemia
progression. We show that AML-associated fusion proteins that64impair differentiation may not alter maintenance of long-term
HSC, while severely compromising their repopulation function.
In addition, we define a preleukemic myeloid progenitor popula-
tion induced by Cbfb-SMMHC that is a target of AML transfor-
mation.
A hallmark of HSCs is their ability to undergo symmetric (per-
petuating HSCs) and asymmetric (differentiating into progeni-
tors that can replenish multilineage hematopoiesis) replication
programs (Weissman, 2000). We show that alterations in these
programs caused by Cbfb-SMMHC closely mimic those result-
ing from Runx1 deficiency (Growney et al., 2005; Ichikawa et al.,
2004). First, Cbfb-SMMHC does not alter the maintenance of
long-term HSCs (called PSCs; see Figure 6) and may remain
in this compartment asymptomatic for long periods. Our find-
ings are in agreement with clinical observations in human
AML. For example, studies in inv(16) samples have shown that
HSCs (CD34+, CD382) harboring CBFB-MYH11 can be present
prenatally and remain undetected for years before progressing
to AML (McHale et al., 2003), and can be detected after diagno-
sis (Haase et al., 1995; Mehrotra et al., 1995). In addition, inv(16)
patients in remission can remain CBFB-MYH11 positive 2 years
after allogenic BM transplantation (Costello et al., 1997; Tobal
et al., 1995). Interestingly, the other frequent CBF leukemia fu-
sion protein RUNX1-ETO has been shown to expand HSCs
and hematopoietic progenitors in mouse and human cells (de
Guzman et al., 2002; Higuchi et al., 2002; Mulloy et al., 2002;
Tonks et al., 2003). This contrast suggests that Cbfb-SMMHC
and RUNX1-ETOmay affect different programs during leukemia
progression.
Second, as PSCs undergo asymmetric replication, differenti-
ation programs exhibit lineage-dependent sensitivity to Cbfb-
SMMHC. Under noncompetitive conditions, circulating B cells
and platelet counts were drastically reduced, whereas T cells
and myeloid cells seemed unaffected. These results suggest
that small changes in CBF levels may significantly affect the reg-
ulation of B cell and megakaryocytic differentiation. Interest-
ingly, multilineage repopulation was limited under competitive
conditions, providing in vivo demonstration that Cbfb-SMMHC
expression impairs differentiation and proliferation capacity of
multipotent progenitors.
Importantly, our work also shows that Cbfb-SMMHC induced
distinct phenotypes that cannot be explained by loss of Runx1
function. First, spontaneous AML efficiently developed 4–6
months after induction of the fusion protein. The pathology of
disease resembled that of our previous knockin model inducedCANCER CELL JANUARY 2006
A R T I C L EFigure 6. Proposed model of Cbfb-SMMHC-associated leukemia progression
HSCs have the potential for multilineage differentiation (straight arrows) and self-renewal (curved arrow). HSCs expressing Cbfb-SMMHC generate a preleu-
kemia stem cell (PSC), in which differentiation and proliferation ability are deficient, and create a distinct abnormal myeloid progenitor (AMP) with limited
proliferation potential. Acute myeloid leukemia (AML) can emerge from either PSCs or AMPs after gaining additional mutations, presumably affecting pro-
liferation and survival programs. Leukemic stem cells (LSC) can generate blastlike and monocytic leukemic cells.by chemical or retroviral mutagenesis (Castilla et al., 1999,
2004), emphasizing that despite its pleiotropic effect in differen-
tiation, Cbfb-SMMHC seems to determine a consistent myeloid
leukemia phenotype. The efficiency of AML in our model also
contrasted with the conditional Runx1-Eto knockin, which de-
veloped granulocytic sarcomas and T cell lymphomas only after
ENU treatment (Higuchi et al., 2002). The use of these two
models in parallel comparative in vivo studies may unravel the
mechanism underlying the identified phenotypic differences be-
tween the CBF oncogenes. Second, the preleukemic myeloid
compartment presented distinct AMPs, in contrast to the neu-
trophilic expansion observed in Runx1 null mice. The AMPs pre-
sented the following: (1) a CMP-like function, generatingmyeloid
and erythroid colonies in vitro; (2) low proliferation capacity, as
colonies were significantly smaller; (3) deficient replating capac-
ity; (4) immunophenotype similar to MEPs.
We have used two independent assays to demonstrate that
the efficiency of AML development in this conditional model is
dependent on the size of the Cbfb-SMMHC-expressing progen-
itor pool at risk for transformation. Consistent with this notion, it
is likely that Cbfb+/MYH11 HSCs in the knockin chimeras were di-
luted below a threshold of detectable ‘‘spontaneous’’ disease.
Alternatively, it is possible that, unlike the inducible model, ES
cell-derived Cbfb+/MYH11 HSCs had undergone a selection pro-
cess during embryonic development, and only a subgroup of
cells with reduced oncogenic potential were present in the BM
of the chimeras.
A critical open question is what distinct CBFb-SMMHC func-
tion directs the predisposition to AML development. Myeloid-
erythroid differentiation is tightly regulated by transcription fac-
tors (Tenen, 2003). Recently, it has been suggested that low
expression levels, rather than the absence of some transcription
factors (such asGATA-1, PU.1, andCEBP-a), may induce leuke-
mia (Rosenbauer et al., 2005). Likewise, AMPsmay emerge from
CBFb-SMMHC-induced downregulation of myeloid transcrip-
tion factors. Alternatively, CBFb-SMMHC may effect an alteredCANCER CELL JANUARY 2006balance of the expression and function of the RUNX family
(RUNX1–3), since RUNX binding sites are present in the pro-
moter of the three RUNX genes (Otto et al., 2003). For example,
the expression of RUNX3, a tumor suppressor lost in gastric
cancer (Li et al., 2002), is consistently downregulated in
inv(16)+ AML samples (Gutierrez et al., 2005; Valk et al., 2004).
The striking immunophenotypic similarity between AMPs and
leukemic cells suggest that AMPs may represent a preleukemic
intermediate step toward AML. It has been proposed that HSCs
(and noncommitted progenitors) are targets of transformingmu-
tations, since AML cells, like HSCs, retain self-renewal function
(Reya et al., 2001). Alternatively, committed progenitors can
progress to leukemia when transduced with leukemia fusion on-
cogenes, suggesting that oncogenic function (and effects of vi-
ral insertions) may provide self-renewal and transforming prop-
erties to a short-lived myeloid progenitor (Cozzio et al., 2003;
Huntly et al., 2004). In our study, limiting dilution BM transplan-
tation analysis demonstrated that LKS2 progenitors expressing
Cbfb-SMMHC (enriched with AMPs) can trigger AML with simi-
lar efficiency as LKS+ progenitors (enriched for PSCs), under-
scoring the significance of AMPs as an important target popula-
tion in this mouse model.
Based on this study, we propose a model for Cbfb-SMMHC-
associated leukemia progression (Figure 6). Expression of Cbfb-
SMMHC in HSCs creates a preleukemic population in the
BM composed of PSCs able to both perpetuate and remain
asymptomatic in the HSC compartment for long periods.
PSCs undergoing asymmetric replication have deficient multilin-
eage repopulation capacity and produce AMPs with reduced
proliferative ability. Both preleukemic progenitors can gain mu-
tations (such as activated Ras, c-kit, or upregulation of PlagL2),
presumably enhancing proliferative and survival programs, to
trigger AML. It is expected that (at least) some leukemic cells
(the leukemia stem cells [LSC]) could retain or regain self-re-
newal capacity and produce leukemic cells with blastlike and
monocytic forms.65
A R T I C L EFinally, this conditional knockin mouse model allows the in-
ducible allelic switch from Cbfb to Cbfb-MYH11 in the adult
mouse. This strategy bypasses the embryonic lethality that is
associated with CBFb-SMMHC expression and enables its ac-
tivation in the adult BM. This model will be key for the study of
early Cbfb-MYH11 target genes in hematopoietic progenitors
and the in vivo validation of inv(16) cooperating oncogenes, as
well as for the evaluation of candidate drugs for improved treat-
ment of AML.
Experimental procedures
Targeting experiments
The previously generated Cbfb+/MYH11 embryonic stem cell ES55 (Castilla
et al., 1996) was retargeted to insert the floxed Cbfb exons 5 and 6 at the
Msc1 restriction site of the Cbfb+/MYH11 intron 4 by homologous recombina-
tion (Figure 1A). The pPNT-based targeting construct included a 5.4 kb Xho1-
Msc1 fragment of Cbfb intron 4, a loxP1 site, a 120 bp Hinf1-Xho1 genomic
fragment including the 30 end of intron 4 and part of exon 5, an XhoI-XhoI se-
quence with the in-frame cDNA sequence for the second part of human
CBFB exon 5 and exon 6, a 300 bp Pst1-Pst1 fragment from pCDNA3.1
(Invitrogen, Carlsbad, CA) including the bovine growth hormone polyadeny-
lation signal, a PGK-hygromycin gene, a second loxP1 site, and a 3.5 kb
Msc1-Xho1 genomic fragment of Cbfb intron 4. Three of 75 hygromycin-
resistant ES cells (ES 28, 32, 56) presented the expected bands by Southern
blot analysis of ES cell genomic DNA cut with NcoI and using an internal
(hygromycin probe) and an external probe (MYH11) for hybridization. Chime-
ricmice forCbfb+/56Mwere backcrossed into 129/SvEv background to obtain
heterozygous Cbfb+/56M and homozygous Cbfb56M/56M mice.
Induction of Cbfb-SMMHC expression
To induce Cbfb-SMMHC expression in adult mice, heterozygous Cbfb+/56M
or homozygousCbfb56M/56Mmice were crossed with theMx1-Cre transgenic
mice (generously provided by Klaus Rajewsky, Harvard University; Kuhn
et al., 1995). For induction, floxed primary mice (Mx1Cre+/Cbfb+/56M double
heterozygous) were injected every other day with three doses (unless other-
wise indicated) of 200 mg/dose pIpC (Sigma, St. Louis, MO) intraperitoneally
at 3 weeks of age. BM cells from restored Cbfb+/562M/Mx-cre and similarly
treated Cbfb+/56M control littermates were analyzed 3 to 6 weeks after induc-
tion.
Genotype analysis
The presence of the floxed Cbfb56M allele in mice was determined routinely
by PCR using tail-snip DNA. PCRs included 50 ng of template DNA and
0.2 mM gene-specific primers (hyg-f 50-CCATCGTCGAGATCCAGACATG-30
and hygr-r 50-GTATATGCTCCGCATTGGTCTTG-30; Cre-f 50-CCGGGCTGC
CACGACCAA-30 and Cre-r 50-GGCGCGGCAACACCATTTTT-30). The PCR
samples were denatured at 94ºC for 2 min, followed by 30 cycles of amplifi-
cation (94ºC for 30 s, 56ºC for 30 s, 72ºC for 45 s), and a final extension step at
72ºC for 5 min.
Southern blot analysis
The efficiency of Cre-mediated deletion was analyzed using standard proce-
dures. Briefly, 10 mg genomic DNA from BM, spleen, liver, and thymus were
digested with BamHI, electrophoresed in 1% agarose gel, transferred onto
Hybond-XLmembrane (AmershamBioscience, Piscataway, NJ), and hybrid-
ized with an P32-labeled EcoRI-BamHI fragment of Cbfb intron 4. For visual-
ization, membranes were exposed to Kodak Bio Max X-ray film at 280ºC.
Flow cytometry and cell sorting
For FACS analysis and cell sorting, peripheral blood was extracted from the
retro-orbital sinus, followed by lysis of red blood cells with RBC lysis solution
(Puregene, Gentra Systems, Minneapolis, MN), and the white blood cell pel-
let was resuspended in PBS with 0.5% bovine serum albumin. BM cells iso-
lated from femurs and tibias were resuspended in staining media A (PBS;
0.5% BSA) or staining media B (biotin-, flavin-, and phenol red-deficient
RPMI 1640 [Invitrogen, Carlsbad, CA], 10 mM HEPES [pH 7.2], 0.02% so-
dium azide, 1 mM EGTA, 3% newborn calf serum) and treated for 10 min
on ice with 2.4G2 Fc block (BD Biosciences, San Jose, CA). Cells were66incubated for 20 min on ice with primary antibodies, and washed and bio-
tin-stained cells were incubated with secondary reagents for 15 min on ice.
After two washes, cells were resuspended in 1 mg/ml propidium iodide to ex-
clude dead cells. Primary antibodies included c-kit (2B8)-allophycocyannin
(APC), Sca-1 (E13-161.7) fluorescein isothiocyanate (FITC) or -phycoerythrin
(PE), IL-7R PE-Cy7 or PE, CD34 (RAM34)-PE or APC, CD16/32 FcgRIII/II
(2.4G2)-FITC, CD41 (MWReg30)-PE, CD229.1 (Ly-9.1) (30C7)-FITC, and
CD45.1 (Ly-5.1) (A20)-PE. (BD Biosciences, San Jose, CA; eBiosciences,
San Diego, CA). In addition, B220 (RA3-6B2), CD19, IgM (clone 331), CD3
(17A2), CD4 (L3T4), CD8 (53-6.7), Gr-1 (R86-8C5), Mac-1 (M1/70), Ter119
(Ly-76) conjugated with biotin, FITC, PE, APC, or PerCP-Cy5.5 (also from
BD Biosciences). Secondary reagents used were streptavidin (SA)-APC or
PerCP-Cy5.5 (BD Biosciences, San Jose, CA). Flow cytometry was per-
formed on a 3 laser, 9 detector LSR II (BD Biosciences, San Jose CA) or
a 3 laser, 7 detector DIVA FACSVantage and analyzed with FlowJo software
(Tree Star, Ashland, OR). For sorting experiments, Lin+ cells were partially re-
moved by negative selection magnetic capture following the procedure sug-
gested by the manufacturer (EasySep, StemCell Technologies, Vancouver
BC). Cells were sorted using antibodies as previously described (Akashi
et al., 2000; Morrison et al., 1997; Morrison and Weissman, 1994). Pheno-
typic populations were defined as HSC (Lin2/c-kithi/Sca-1hi), CMP (Lin2/c-
kithi/Sca-12/CD34+/CD16/32lo), GMP (Lin2/c-kithi/Sca-12/CD34+/CD16/32hi),
and MEP (Lin2/c-kithi/Sca-12/CD342/CD16/32lo). The purity of the sorted
populations was approximately 91%–98% by FACS analysis.
Ploidy analysis of megakaryocytes
BM cells isolated in CATCH media were treated 10 min on ice with 2.4G2 Fc
block (BD Biosciences, San Jose, CA) before staining with CD41-FITC anti-
body (BD Biosciences, San Jose, CA) on ice for 30 min. After 2 washes, cells
were incubated with propidium iodide (50 mg/ml) in hypotonic buffer (0.1%
sodium citrate; 0.1% Triton X-100 and 50 mg/ml RNaseA) for 30 min at
room temperature. Flow cytometric analysis was performed as previously
described (Growney et al., 2005; Ichikawa et al., 2004; Jackson et al., 1984).
Transplantation experiments
NCRA
BMcells (13 106) fromCbfb562M/+/Mx-cre (floxed) or control mice (test mice:
129Sv/Ev; Ly9.1+) were transplanted into lethally irradiated (1300 rads) wild-
type C57BL/6 (Ly9.2+/Ly5.2+) mice. Engraftment of test cells was confirmed
before the administration of seven doses of pIpC every other day, 2 weeks
after transplantation. Isotype-specific antibody FITC-Ly9.1 (BD Biosciences,
San Jose, CA) was used to determine the donor-derived population by FACS
analysis. Peripheral bloodwas analyzed every 2weeks for 12weeks. BMwas
analyzed at 18 weeks, at which time 13 106 cells were transplanted into sec-
ondary recipients.
CRA
Test (floxed or wild-type control; 129SvEv; Ly9.1+/Ly5.2+) BM cells (53 105)
were mixed with equal numbers of wild-type competitor (C57BL/6-SJL;
Ly9.2+/Ly5.1+) BM cells and injected intravenously into lethally irradiated
(1300 rads) C57BL/6 (Ly9.2+/Ly5.2+) mice. Engraftment of test cells was con-
firmed before the administration of seven doses of pIpC every other day
2 weeks after transplantation. The isotype-specific antibodies FITC-Ly9.1
and PE-Ly5.1 (BD Biosciences, San Jose, CA) were used to determine the
origins of repopulating cells by FACS analysis. Peripheral blood was ana-
lyzed before induction and biweekly afterwards by Wright-Giemsa staining
and FACS analysis. BM cells were analyzed 18 weeks after induction; 1 3
106 cells were transplanted into lethally irradiated recipients.
Limited dilution transplantation assays
LKS+ and LKS2 populations from primary restored mice were sorted and
transduced with MIG-PLAGL2 as previously described (Cozzio et al.,
2003). Sublethally irradiated (650 rads) wild-type mice were transplanted
with the indicated number of cells (104, 103, 102). The percentage of
PLAGL2-transduced GFP-positive cells was measured after 2 days of in vitro
culture and was used to estimate the number of transduced cells. Mice were
monitored for a period of 6 months for signs of leukemia.
Western blot analysis
BMcells were solubilized in RIPA lysis buffer (150mMNaCl, 1%NP-40, 0.5%
sodium deoxycholate, 0.1% SDS, 50 mM Tris [pH 8.0]) containing a cocktail
of protease inhibitors (Calbiochem, San Diego, CA). Protein concentrationsCANCER CELL JANUARY 2006
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Hercules, CA). Twenty micrograms of protein lysate were electrophoresed
in 12% SDS-polyacrylamide gel and transferred to PVDF membranes (Bio-
Rad, Hercules, CA). Blots were probed with one of the following antibodies:
mouse monoclonal anti-Cbfb-Ab (b141, kindly provided by Nancy Speck,
Dartmouth Medical School) or mouse anti-a-tubulin (Sigma, St. Louis, MO)
followed by a 1 hr incubation with horseradish peroxidase-conjugated anti-
mouse Ig-Ab (Jackson ImmunoResearch Labs, West Grove, PA). Immuno-
blots were developed using luminol-based enhanced chemiluminescence
(Amersham Pharmacia, Piscataway, NJ) and autoradiography.
In vitro differentiation assays
BM cells (13 104) were isolated from primary, control, or leukemic mice and
cultured in methylcellulose (M3434, StemCell Technologies, Vancouver BC).
CFU-E and BFU-E were scored after 2 days and 3 days of culture, respec-
tively. The total numbers of myeloid and mixed colonies were counted after
7 days of culture in 5% CO2 at 37ºC. Single colonies were isolated for
PCR genotyping and cytology analyses. Myeloid CFUs (blast, GEMM, GM,
G and M) were identified based on the morphology of cytospin preparations
from 70 to 100 individual colonies. In serial replating experiments, the colony
number was scored at day 7, cells were pooled, and 13 104 cells were plated
for subsequent culture.
Histology and cytology analyses
Tissue samples (spleen, liver, tibia, lung, thymus, lymph nodes, brain, epithe-
lium) collected from leukemic mice were fixed in 10% buffered formalin and
embedded in paraffin, and sectioned specimens were stained with H&E. For
cytological and morphological analysis, cyto-centrifuged preparations were
stained with Wright-Giemsa (Fisher Scientific, Pittsburgh, PA). Other stains
included Sudan Black B, Naphthol AS-D Chloroacetate Esterase (CAE),
and a-Naphthyl Acetate Esterase (all from Sigma Aldrich, St. Louis, MO).
Stains were performed according to the manufacturer’s instructions, except
that CAE-stained slides were incubated 30 min.
Quantitative RT-PCR
RNA from leukemic samples was extracted with Trizol reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s protocol. First-strand cDNA
was generated using 2 mg total RNA, 200 U SuperScript III reverse transcrip-
tase (Invitrogen, Carlsbad, CA), and 0.5 mg oligo dT primer in a 20 ml reaction.
QPCR was performed using SYBR green PCR master mix (Applied Biosys-
tems, Foster City, CA) containing 0.2 mMgene-specific primers and detected
in ABI PRISM 7000 sequence detection system (Applied Biosystems, Foster
City, CA) according to the manufacturer’s instructions. Primers for Plag1
were mP1x1 (50-GGTTCACTCCTTCTCTCACACG-30) and mP1X2 (50-TGAG
TAGCCATGTGCCTTTGTA-30), and primers for Plagl2 were mPL2x1 (50-TA
TAGGCACATGGCCACCCACT-30) and hL2R3 (50-GTACTCTCAAAGGTCTG
CAGG-30). Samples were normalized to b-actin expression levels (forward
primer, 50-CGAGGCCCAGAGCAAGAGAG-30; reverse primer, 50-CGGTTGG
CCTTAGGGTTCAG-30), and the RELs were determined by the standard
curve method.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures,
two supplemental figures, and one supplemental table and can be found
with this article online at http://www.cancercell.org/cgi/content/full/9/1/57/
DC1/.
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